Farshad Guirakhoo Ph D
About
Farshad Guirakhoo Ph D is from Geneva Metropolitan Area. Farshad works in the following industries: "Biotechnology Research". Farshad is currently CSO Vaxxinity at Vaxxinity, located in Dallas, Texas, United States. Farshad also works as Co-Founder & CEO at Responsive Bioservices, a job Farshad has held since Jan 2017. In Farshad's previous role as a Chief Scientific Officer at COVAXX, Farshad worked in New York, United States until Apr 2021. Prior to joining COVAXX, Farshad was a Chief Scientific Officer at United Neuroscience at https://www.unitedneuroscience.com and held the position of Chief Scientific Officer at United Neuroscience at New York City Metropolitan Area. Prior to that, Farshad was a Chief Scientific Officer at GeoVax, Inc., based in Smyrna, GA from Oct 2016 to Aug 2020. Farshad started working as Senior Vice President Research & Development at GeoVax Labs, Inc. in Smyrna, GA in Oct 2015. From Aug 2014 to Apr 2015, Farshad was Chief Technology Officer at Vaxess Technologies, based in Cambridge, MA. Prior to that, Farshad was a Chief Scientific Officer at Hookipa Biotech AG, based in Vienna, Austria from Oct 2012 to Apr 2014. Farshad started working as Sr Director External R&D at Sanofi Pasteur in Sanofi Pasteur Lyon, France and Cambridge, MA in Jul 2007.
Go to finalscout.com and type Farshad Guirakhoo Ph D's name into the search box for a free email address. FinalScout is a professional database with more than 500 million business professionals and 200 million company executives.
Farshad Guirakhoo Ph D's current jobs
Responsive BioServices (RBS) is a Contract Research Organization (CRO) providing laboratory testing in the fields of virology and immunology along with a suite of complementary services. Our core service offering is the development, execution, and reporting of viral load and immunogenicity testing of samples from clinical trials and animal studies. We also provide a broad range of supporting and ancillary services including assay validation, quality and regulatory support, reference standard production and characterization, and scientific consulting. For more info see www.itsrbs.com
Farshad Guirakhoo Ph D's past jobs
COVAXX, a division of United Biomedical, is responding to the COVID-19 breakout in a manner that is consistent with our values by following the science and putting diagnostics and solutions-thinking at the center of our approach. Our priority is to stay on the front lines to safeguard the health and well-being of our communities. We have already deployed our antibody tests in several states in the U.S., China, and Taiwan. We are a high throughput antibody test and are actively working with communities and institutions to help detect and contain community spread. In addition, COVAXX is developing the first Multitope Peptide-Based Vaccine that has shown promising efficacy in animals and is based on a commercially proven, safe and scalable vaccine platform. We are entering human trials later this summer. Our mission and vision is to save and safeguard lives by tackling the global COVID-19 pandemic using cost-effective, scalable, and proven science-based solutions delivered to the world.
CORPORATE PROFILE GeoVax Labs, Inc., a clinical-stage biotechnology company, is developing human vaccines against infectious diseases and cancer using a novel patented Modified Vaccinia Ankara-Virus Like Particle (MVA-VLP) vector vaccine platform. In this platform, MVA, a large virus capable of carrying several vaccine antigens, which are expressed as highly effective VLP immunogens in the person being vaccinated. The platform elicits durable vaccine responses while providing the safety characteristics of a replication defective vector. Our development programs are currently focused on preventive vaccines against HIV, Zika Virus, hemorrhagic fever (HF) viruses (Ebola, Sudan, Marburg, Lassa) and malaria, as well as therapeutic vaccines for chronic Hepatitis B Virus (HBV) infections and cancers. Our HIV program has received substantial federal support (>$50M) from the NIH. • Confirmed safety and durable immunogenicity of MVA-VLP-HIV vaccine in clinical trials involving 500 participants. • Advancing our HIV program to efficacy studies in NIH-supported clinical trials; most clinically developed HIV vaccine for clade B, the subtyp prevalent in the developed world, an important commercial market. • Promising Zika vaccine with multiple collaborators. • Tetravalent HF vaccine offers the potential for single-dose protection against lethal viral HFs endemic/epidemic to Africa and greater safety than current single dose replicating vectors. • Cancer immunotherapy program has potential for multiple high-value disease targets. • A combination novel immunotherapeutic approach for chronic HBV infections. • A multi-antigen MVA-VLP malaria vaccine being developed with a leader in the field of malaria vaccines.
Lead the company’s research and development programs
Oversaw Research and Development for vaccine candidates against cytomegalovirus infectious using a novel replication deficient viral vector
Identifying and evaluating external opportunities within NGO, government organizations, universities and biotechnology institutions in the areas of vaccines and therapeutics for infectious disease
Constructions, preclinical testings, and clinical evaluations of vaccines and therapeutics for infectious diseases
Structural and molecular analysis of Flavivirus envelope proteins